{"url_path":"/sec/allo/8-k/2026-06-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-044618-index.html","accession_number":"0001628280-26-044618","cik":"0001737287","ticker":"ALLO","issuer_name":"Allogene Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-044618-index.html","primary_entity_key":"0001737287","primary_entity_name":"Allogene Therapeutics, Inc."},"word_count":104,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits.\n\n(d)\n\nExhibit\nNumberDescription\n\n3.1\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company, effective June 18, 2026.](exhibit31toform2026annualm.htm)\n\n5.1\n[Opinion of Cooley LLP](exhibit51toformjune2026pro.htm)\n\n23.1\n[Consent of Cooley LLP (included in Exhibit 5.1)](exhibit51toformjune2026pro.htm)\n\n104The cover page of this report has been formatted in Inline XBRL.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nALLOGENE THERAPEUTICS, INC.\n\nBy:/s/ David Chang, M.D., Ph.D.\n\nDavid Chang, M.D., Ph.D.\n\nPresident, Chief Executive Officer\n\nDated: June 22, 2026"}